TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double-Blind, Randomized, Placebo-Controlled, Multicenter Phase III Study of Intravenous Terlipressin in Patients With Hepatorenal Syndrome Type 1
Brief Summary: The purpose of this study is to determine whether terlipressin is safe and effective in the treatment of patients with hepatorenal syndrome (HRS) type 1 when compared to placebo.


Options:
A: Arm Label: Terlipressin and Type-2 HRS; Type: ACTIVE_COMPARATOR; Interventions: Drug: Noradrenaline, Drug: Terlipressin | Arm Label: Noradrenaline and Type-2 HRS; Type: ACTIVE_COMPARATOR; Interventions: Drug: Noradrenaline, Drug: Terlipressin | Intervention Type: DRUG; Name: Noradrenaline; Assigned to Arm(s): Noradrenaline and Type-2 HRS, Terlipressin and Type-2 HRS | Intervention Type: DRUG; Name: Terlipressin; Assigned to Arm(s): Noradrenaline and Type-2 HRS, Terlipressin and Type-2 HRS
B: Arm Label: Terlipressin; Type: EXPERIMENTAL; Interventions: Drug: Terlipressin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Terlipressin; Assigned to Arm(s): Terlipressin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Terlipressin | Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Noradrenalin | Intervention Type: DRUG; Name: Terlipressin; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Noradrenalin; Assigned to Arm(s): 1
D: Arm Label: Terlipressin; Type: EXPERIMENTAL; Interventions: Drug: terlipressin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: terlipressin; Assigned to Arm(s): Terlipressin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double-Blind, Randomized, Placebo-Controlled, Multicenter Phase III Study of Intravenous Terlipressin in Patients With Hepatorenal Syndrome Type 1
Brief Summary: The purpose of this study is to determine whether terlipressin is safe and effective in the treatment of patients with hepatorenal syndrome (HRS) type 1 when compared to placebo.


Options:
A: Arm Label: Terlipressin and Type-2 HRS; Type: ACTIVE_COMPARATOR; Interventions: Drug: Noradrenaline, Drug: Terlipressin | Arm Label: Noradrenaline and Type-2 HRS; Type: ACTIVE_COMPARATOR; Interventions: Drug: Noradrenaline, Drug: Terlipressin | Intervention Type: DRUG; Name: Noradrenaline; Assigned to Arm(s): Noradrenaline and Type-2 HRS, Terlipressin and Type-2 HRS | Intervention Type: DRUG; Name: Terlipressin; Assigned to Arm(s): Noradrenaline and Type-2 HRS, Terlipressin and Type-2 HRS
B: Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Terlipressin | Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Noradrenalin | Intervention Type: DRUG; Name: Terlipressin; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Noradrenalin; Assigned to Arm(s): 1
C: Arm Label: Terlipressin; Type: EXPERIMENTAL; Interventions: Drug: Terlipressin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Terlipressin; Assigned to Arm(s): Terlipressin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Terlipressin; Type: EXPERIMENTAL; Interventions: Drug: terlipressin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: terlipressin; Assigned to Arm(s): Terlipressin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Androgen-Deprivation Therapy for Non-metastatic Prostate Cancer
Brief Summary: This study will evaluate AMG 162 in the treatment of bone loss in subjects undergoing Androgen-Deprivation Therapy for Non-metastatic Prostate Cancer.


Options:
A: Arm Label: IV Bisphosphonates q 4 weeks; Type: ACTIVE_COMPARATOR; Interventions: Drug: IV Bisphosphonate q 4 weeks | Arm Label: 180 mg AMG 162 (SC) q 12 weeks; Type: EXPERIMENTAL; Interventions: Genetic: AMG 162 180 mg (SC) q 12 weeks | Arm Label: 180 mg AMG 162 (SC) q 4 weeks; Type: EXPERIMENTAL; Interventions: Genetic: AMG 162- 180 mg q 4 weeks | Intervention Type: GENETIC; Name: AMG 162 180 mg (SC) q 12 weeks; Assigned to Arm(s): 180 mg AMG 162 (SC) q 12 weeks | Intervention Type: DRUG; Name: IV Bisphosphonate q 4 weeks; Assigned to Arm(s): IV Bisphosphonates q 4 weeks | Intervention Type: GENETIC; Name: AMG 162- 180 mg q 4 weeks; Assigned to Arm(s): 180 mg AMG 162 (SC) q 4 weeks
B: Arm Label: AMG 162; Type: EXPERIMENTAL; Interventions: Drug: AMG 162 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: AMG 162; Assigned to Arm(s): AMG 162 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Zoledronic acid + androgen deprivation therapy; Type: EXPERIMENTAL; Interventions: Drug: zoledronic acid, Drug: androgen deprivation therapy, Drug: GnRH agonist, Dietary Supplement: Calcium supplement, Dietary Supplement: Vitamin D | Arm Label: Placebo + androgen deprivation therapy; Type: ACTIVE_COMPARATOR; Interventions: Other: placebo, Drug: androgen deprivation therapy, Drug: GnRH agonist, Dietary Supplement: Calcium supplement, Dietary Supplement: Vitamin D | Intervention Type: DRUG; Name: zoledronic acid; Assigned to Arm(s): Zoledronic acid + androgen deprivation therapy | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Placebo + androgen deprivation therapy | Intervention Type: DRUG; Name: androgen deprivation therapy; Assigned to Arm(s): Placebo + androgen deprivation therapy, Zoledronic acid + androgen deprivation therapy | Intervention Type: DRUG; Name: GnRH agonist; Assigned to Arm(s): Placebo + androgen deprivation therapy, Zoledronic acid + androgen deprivation therapy | Intervention Type: DIETARY_SUPPLEMENT; Name: Calcium supplement; Assigned to Arm(s): Placebo + androgen deprivation therapy, Zoledronic acid + androgen deprivation therapy | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D; Assigned to Arm(s): Placebo + androgen deprivation therapy, Zoledronic acid + androgen deprivation therapy
D: Intervention Type: DRUG; Name: clodronate disodium; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: mitoxantrone hydrochloride; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: prednisone; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: quality-of-life assessment; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Impact of CPAP on Functional Outcomes in Milder Obstructive Sleep Apnea (CATNAP)
Brief Summary: The purpose of this study is to determine whether functional status improves in individuals with milder obstructive sleep apnea (OSA) following continuous positive airway pressure (CPAP) treatment.


Options:
A: Arm Label: Active Treatment; Type: ACTIVE_COMPARATOR; Interventions: Device: Continuous Positive Airway Pressure (CPAP) Treatment | Arm Label: Sham/Placebo Treatment; Type: PLACEBO_COMPARATOR; Interventions: Device: Sham CPAP device - CPAP device with pressure delivered <1 cm H20 | Intervention Type: DEVICE; Name: Continuous Positive Airway Pressure (CPAP) Treatment; Assigned to Arm(s): Active Treatment | Intervention Type: DEVICE; Name: Sham CPAP device - CPAP device with pressure delivered <1 cm H20; Assigned to Arm(s): Sham/Placebo Treatment
B: Arm Label: NPPV group; Type: EXPERIMENTAL; Interventions: Device: ventilators designed for non invasive ventilation | Arm Label: control gorup; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: ventilators designed for non invasive ventilation; Assigned to Arm(s): NPPV group
C: Arm Label: COPD subjects; Type: N/A; Interventions: Other: Novel endpoint determination | Arm Label: Smoker controls; Type: N/A; Interventions: Other: Novel endpoint determination | Arm Label: Non-smoker controls; Type: N/A; Interventions: Other: Novel endpoint determination | Intervention Type: OTHER; Name: Novel endpoint determination; Assigned to Arm(s): COPD subjects, Non-smoker controls, Smoker controls
D: Arm Label: Long Term Oxygen Therapy; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Non Invasive Ventilation; Type: ACTIVE_COMPARATOR; Interventions: Device: Non Invasive Ventilation | Intervention Type: DEVICE; Name: Non Invasive Ventilation; Assigned to Arm(s): Non Invasive Ventilation

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Study to Evaluate Denosumab in the Treatment of Postmenopausal Osteoporosis FREEDOM (Fracture REduction Evaluation of Denosumab in Osteoporosis Every 6 Months)
Brief Summary: This study will evaluate the effectiveness and safety of denosumab in treating women with Postmenopausal Osteoporosis.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: Denosumab 60 mg Q6M; Type: EXPERIMENTAL; Interventions: Drug: Denosumab | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Denosumab; Assigned to Arm(s): Denosumab 60 mg Q6M
B: Intervention Type: DRUG; Name: Zoledronic Acid; Assigned to Arm(s): N/A
C: Arm Label: Denosumab; Type: EXPERIMENTAL; Interventions: Biological: Denosumab | Intervention Type: BIOLOGICAL; Name: Denosumab; Assigned to Arm(s): Denosumab
D: Intervention Type: DRUG; Name: Zoledronic Acid; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Study to Evaluate Denosumab in the Treatment of Postmenopausal Osteoporosis FREEDOM (Fracture REduction Evaluation of Denosumab in Osteoporosis Every 6 Months)
Brief Summary: This study will evaluate the effectiveness and safety of denosumab in treating women with Postmenopausal Osteoporosis.


Options:
A: Arm Label: Paricalcitol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Paricalcitol | Arm Label: Matching placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Paricalcitol; Assigned to Arm(s): Paricalcitol | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Matching placebo
B: Intervention Type: DRUG; Name: Cinacalcet HCl; Assigned to Arm(s): N/A
C: Arm Label: Denosumab; Type: EXPERIMENTAL; Interventions: Drug: Denosumab (Prolia) | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Denosumab (Prolia); Assigned to Arm(s): Denosumab
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: Denosumab 60 mg Q6M; Type: EXPERIMENTAL; Interventions: Drug: Denosumab | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Denosumab; Assigned to Arm(s): Denosumab 60 mg Q6M

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Study to Evaluate Denosumab in the Treatment of Postmenopausal Osteoporosis FREEDOM (Fracture REduction Evaluation of Denosumab in Osteoporosis Every 6 Months)
Brief Summary: This study will evaluate the effectiveness and safety of denosumab in treating women with Postmenopausal Osteoporosis.


Options:
A: Arm Label: Denosumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Denosumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Denosumab; Assigned to Arm(s): Denosumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Intervention Type: DRUG; Name: Zoledronic Acid; Assigned to Arm(s): N/A
C: Arm Label: Neridronato; Type: EXPERIMENTAL; Interventions: Drug: Neridronate | Arm Label: Placebo; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Neridronate; Assigned to Arm(s): Neridronato
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: Denosumab 60 mg Q6M; Type: EXPERIMENTAL; Interventions: Drug: Denosumab | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Denosumab; Assigned to Arm(s): Denosumab 60 mg Q6M

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Study to Evaluate Denosumab in the Treatment of Postmenopausal Osteoporosis FREEDOM (Fracture REduction Evaluation of Denosumab in Osteoporosis Every 6 Months)
Brief Summary: This study will evaluate the effectiveness and safety of denosumab in treating women with Postmenopausal Osteoporosis.


Options:
A: Intervention Type: DRUG; Name: alendronate; Assigned to Arm(s): N/A
B: Arm Label: Romosozumab; Type: EXPERIMENTAL; Interventions: Drug: Romosozumab, Drug: Denosumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Denosumab | Intervention Type: DRUG; Name: Romosozumab; Assigned to Arm(s): Romosozumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Denosumab; Assigned to Arm(s): Placebo, Romosozumab
C: Intervention Type: DRUG; Name: alendronate (Fosamax); Assigned to Arm(s): N/A
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: Denosumab 60 mg Q6M; Type: EXPERIMENTAL; Interventions: Drug: Denosumab | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Denosumab; Assigned to Arm(s): Denosumab 60 mg Q6M

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Study to Evaluate Denosumab in the Treatment of Postmenopausal Osteoporosis FREEDOM (Fracture REduction Evaluation of Denosumab in Osteoporosis Every 6 Months)
Brief Summary: This study will evaluate the effectiveness and safety of denosumab in treating women with Postmenopausal Osteoporosis.


Options:
A: Intervention Type: DRUG; Name: Zoledronic Acid; Assigned to Arm(s): N/A
B: Arm Label: Zoledronic Acid 2x5 mg; Type: EXPERIMENTAL; Interventions: Drug: Zoledronic Acid | Arm Label: Zoledronic Acid 1x5 mg; Type: EXPERIMENTAL; Interventions: Drug: Zoledronic Acid, Drug: Placebo | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Zoledronic Acid; Assigned to Arm(s): Zoledronic Acid 1x5 mg, Zoledronic Acid 2x5 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo, Zoledronic Acid 1x5 mg
C: Intervention Type: DRUG; Name: Zoledronic Acid; Assigned to Arm(s): N/A
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: Denosumab 60 mg Q6M; Type: EXPERIMENTAL; Interventions: Drug: Denosumab | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Denosumab; Assigned to Arm(s): Denosumab 60 mg Q6M

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Early Glycoprotein IIb/IIIa Inhibition in Non-ST-segment Elevation Acute Coronary Syndrome: A Randomized, Placebo-Controlled Trial Evaluating the Clinical Benefits of Early Front-loaded Eptifibatide in the Treatment of Patients With Non-ST-segment Elevation Acute Coronary Syndrome (EARLY ACS)
Brief Summary: The purpose of this study is to see if early INTEGRILIN® (eptifibatide) therapy in patients with non-ST-segment elevation acute coronary syndrome (ACS) reduces the occurence of death, heart attack and urgent cardiac intervention (surgery) compared to placebo (with delayed provisional use of eptifibatide).


Options:
A: Arm Label: Apixaban; Type: EXPERIMENTAL; Interventions: Drug: Apixaban | Arm Label: Acetylasalicylic acid; Type: ACTIVE_COMPARATOR; Interventions: Drug: Acetylsalicylic acid | Intervention Type: DRUG; Name: Apixaban; Assigned to Arm(s): Apixaban | Intervention Type: DRUG; Name: Acetylsalicylic acid; Assigned to Arm(s): Acetylasalicylic acid
B: Arm Label: Active Clonidine and Active ASA; Type: EXPERIMENTAL; Interventions: Drug: Active Clonidine, Drug: Active ASA | Arm Label: Active Clonidine and Placebo ASA; Type: EXPERIMENTAL; Interventions: Drug: Active Clonidine, Drug: Placebo ASA | Arm Label: Placebo Clonidine and Active ASA; Type: EXPERIMENTAL; Interventions: Drug: Placebo Clonidine, Drug: Active ASA | Arm Label: Placebo Clonidine and Placebo ASA; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo Clonidine, Drug: Placebo ASA | Intervention Type: DRUG; Name: Active Clonidine; Assigned to Arm(s): Active Clonidine and Active ASA, Active Clonidine and Placebo ASA | Intervention Type: DRUG; Name: Placebo Clonidine; Assigned to Arm(s): Placebo Clonidine and Active ASA, Placebo Clonidine and Placebo ASA | Intervention Type: DRUG; Name: Active ASA; Assigned to Arm(s): Active Clonidine and Active ASA, Placebo Clonidine and Active ASA | Intervention Type: DRUG; Name: Placebo ASA; Assigned to Arm(s): Active Clonidine and Placebo ASA, Placebo Clonidine and Placebo ASA
C: Arm Label: Prasugrel; Type: EXPERIMENTAL; Interventions: Drug: Prasugrel, Drug: Commercially-available Aspirin | Arm Label: Clopidogrel; Type: ACTIVE_COMPARATOR; Interventions: Drug: Clopidogrel, Drug: Commercially-available Aspirin | Intervention Type: DRUG; Name: Clopidogrel; Assigned to Arm(s): Clopidogrel | Intervention Type: DRUG; Name: Prasugrel; Assigned to Arm(s): Prasugrel | Intervention Type: DRUG; Name: Commercially-available Aspirin; Assigned to Arm(s): Clopidogrel, Prasugrel
D: Arm Label: Eptifibatide; Type: EXPERIMENTAL; Interventions: Drug: Eptifibatide (Integrilin) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Eptifibatide (Integrilin); Assigned to Arm(s): Eptifibatide | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Early Glycoprotein IIb/IIIa Inhibition in Non-ST-segment Elevation Acute Coronary Syndrome: A Randomized, Placebo-Controlled Trial Evaluating the Clinical Benefits of Early Front-loaded Eptifibatide in the Treatment of Patients With Non-ST-segment Elevation Acute Coronary Syndrome (EARLY ACS)
Brief Summary: The purpose of this study is to see if early INTEGRILIN® (eptifibatide) therapy in patients with non-ST-segment elevation acute coronary syndrome (ACS) reduces the occurence of death, heart attack and urgent cardiac intervention (surgery) compared to placebo (with delayed provisional use of eptifibatide).


Options:
A: Arm Label: Prasugrel; Type: EXPERIMENTAL; Interventions: Drug: Prasugrel | Arm Label: Clopidogrel; Type: ACTIVE_COMPARATOR; Interventions: Drug: Clopidogrel | Intervention Type: DRUG; Name: Prasugrel; Assigned to Arm(s): Prasugrel | Intervention Type: DRUG; Name: Clopidogrel; Assigned to Arm(s): Clopidogrel
B: Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Catheterization immediate PCI | Arm Label: 1; Type: EXPERIMENTAL; Interventions: Procedure: delayed PCI | Intervention Type: PROCEDURE; Name: Catheterization immediate PCI; Assigned to Arm(s): 2 | Intervention Type: PROCEDURE; Name: delayed PCI; Assigned to Arm(s): 1
C: Arm Label: Radial; Type: EXPERIMENTAL; Interventions: Procedure: Radial approach | Arm Label: Femoral; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Femoral approach | Intervention Type: PROCEDURE; Name: Femoral approach; Assigned to Arm(s): Femoral | Intervention Type: PROCEDURE; Name: Radial approach; Assigned to Arm(s): Radial
D: Arm Label: Eptifibatide; Type: EXPERIMENTAL; Interventions: Drug: Eptifibatide (Integrilin) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Eptifibatide (Integrilin); Assigned to Arm(s): Eptifibatide | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase II Clinical Trial Testing the Safety and Efficacy of 3,4-Methylenedioxymethamphetamine (MDMA)-Assisted Psychotherapy in Subjects With Chronic Posttraumatic Stress Disorder
Brief Summary: The goal of this clinical trial is to compare MDMA-assisted therapy to placebo with therapy in people with chronic, treatment-resistant posttraumatic stress disorder (PTSD). The main question it aims to answer is: Is there a reduction in PTSD symptoms among people given MDMA-assisted therapy compared to placebo with therapy?

Participants will receive either MDMA-assisted therapy or placebo with therapy during two blinded experimental sessions spaced three to five weeks apart. During experimental sessions, participants receive an initial dose of 125 mg of MDMA HCl, or placebo, followed by a dose of 62.5 mg of MDMA HCl, or placebo. During this treatment period, participants will also undergo non-drug preparatory psychotherapy sessions and non-drug integrative sessions.

The study will test whether MDMA-assisted therapy can be safely given to participants. Researchers will compare PTSD symptoms in the MDMA-assisted therapy group to the placebo with therapy group to see if there is a reduction in symptoms after the treatment period.


Options:
A: Arm Label: MDMA-assisted therapy (125 mg); Type: EXPERIMENTAL; Interventions: Drug: Midomafetamine HCl, Behavioral: Therapy | Arm Label: Placebo with therapy; Type: PLACEBO_COMPARATOR; Interventions: Drug: Lactose placebo pill, Behavioral: Therapy | Intervention Type: DRUG; Name: Midomafetamine HCl; Assigned to Arm(s): MDMA-assisted therapy (125 mg) | Intervention Type: DRUG; Name: Lactose placebo pill; Assigned to Arm(s): Placebo with therapy | Intervention Type: BEHAVIORAL; Name: Therapy; Assigned to Arm(s): MDMA-assisted therapy (125 mg), Placebo with therapy
B: Arm Label: study arm; Type: EXPERIMENTAL; Interventions: Behavioral: Psychotherapy treatment | Intervention Type: BEHAVIORAL; Name: Psychotherapy treatment; Assigned to Arm(s): study arm
C: Arm Label: MBSR; Type: EXPERIMENTAL; Interventions: Behavioral: Mindfulness-based stress reduction | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Mindfulness-based stress reduction; Assigned to Arm(s): MBSR
D: Arm Label: A; Type: EXPERIMENTAL; Interventions: Behavioral: NET | Arm Label: B; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: NET; Assigned to Arm(s): A

Answer: A